Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide, Subcutaneous Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma
NCT02441686Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Dec 2015
- Primary completion
- Dec 2021
- Modality
- Modified Peptides, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib, lenalidomide and dexamethasone in multiple myeloma (MM), sponsored by Dana-Farber Cancer Institute. Primary endpoints: 4-Cycle Induction Overall Response Rate at 12 weeks, Induction Overall Response Rate at 24 weeks and 2 more. Started Dec 2015; status: completed.
02
Drugs
bortezomiblenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02441686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02441686.